Absci Corporation (ABSI) Stock

Absci Corporation (ABSI) is a Technology stock trading at $7.39 (as of 2026-06-18), with a market capitalization of $926.08M and a trailing P/E of -8.3. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Absci Corporation is engaged in drug and target discovery, providing biologic drug candidate programs and production cell lines for partners. It offers an integrated platform that connects discovery activities with cell line development as part of a unified workflow for biologics in the United States.

Valuation — source: SEC EDGAR (first-party)
Price$7.39
Market Cap$926.08M
P/E Ratio-8.3
EV / EBITDA-9.4
Price / Book6.16
Price / Sales577.43
DCF Value (model)$-10.32
DCF Upside vs Price-239.6%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$2.80M
Net Margin-4113.7%
Return on Equity-68.9%
Debt / Equity0.02
Current Ratio6.59
Revenue Growth (YoY)-38.2%
EPS Growth (YoY)-10.6%
FCF Growth (YoY)29.2%
Financial Health — source: SEC EDGAR
Altman Z-Score20.11 (safe)
Valuation vs Sector & Industry
Stock P/E-8.3
Sector P/E (Technology)32.6
Industry P/E (Business Services)27.1
vs Sector-125.4%
vs Industry-130.6%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderFMR LLC ($67.65M)
Institutional Holders Tracked10
Company
SectorTechnology
IndustryBusiness Services
CEOSean McClain
Employees156
CountryUS
IPO Date2022-03-22

Related Companies (Business model: Clinical Labs / CRO Services; 8 closest by market cap; US-domiciled)

  • CareDx, Inc (CDNA)
  • Fulgent Genetics, Inc. (FLGT)
  • Personalis, Inc. (PSNL)
  • Myriad Genetics, Inc. (MYGN)
  • National Research Corporation (NRC)
  • OmniAb, Inc. (OABI)
  • Achieve Life Sciences, Inc. (ACHV)
  • Insight Molecular Diagnostics Inc. (IMDX)
ABSI earnings history · ABSI institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.